IP Library Granted Patent US 8,338,394
Granted Patent B2
US 8,338,394 · App. 12/445,100 · Granted Dec 25, 2012

Methods for treating metabolic diseases

Assignee: Case Western Reserve University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,338,394
App. No.
12/445,100
Granted
Dec 25, 2012
Kind
B2
Abstract

A pharmaceutical composition for treating a metabolic disease in a mammalian subject includes a therapeutically effective amount of all-trans-13,14-dihydroretinoid, all-trans-13,14-dihydroretinoid derivative, or agent capable of modulating the level of at least one all-trans-13,14-dihydroretinoid or all-trans-13,14-dihydroretinoid derivative in the subject.

Claims (8)

1. A method of treating a metabolic disease in a mammalian subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one all-trans-13,14-dihydroretinoid, all-trans-13,14-dihydroretinoid derivative, all-trans-retinol:all-trans-13,14-dihydroretinol saturase or a compound that modulates the level and/or activity of all-trans-retinol:all-trans-13,14-dihydroretinol saturase, wherein the metabolic disease involves insulin secretion, glucose uptake or fatty acid oxidation.

2. The method of claim 1 , the pharmaceutical composition being administered to at least one cell expressing G-protein-coupled receptor 40 (GPR40) and/or a polynucleotide encoding GPR40.

3. The method of claim 1 , the pharmaceutical composition promoting lipolysis in the subject.

4. The method of claim 1 , the pharmaceutical composition promoting hepatic uptake and esterification of free fatty acids.

5. The method of claim 1 , the pharmaceutical composition comprising the all-trans-13,14-dihydroretinoid comprising at least one of (R)-all-trans-13,14-dihydroretinol, (S)-all-trans-13,14-dihydroretinol, (R)-all-trans-13,14-dihydroretinoic acid, or (S)-all-trans-13,14-dihydroretinoic acid, or an ester thereof.

6. The method of claim 5 , the metabolic disease including obesity or an obesity-related condition.

7. The method of claim 5 , the pharmaceutical composition comprising at least 75% of (R)-all-trans-13,14-dihydroretinol, (R)-all-trans-13,14-dihydroretinoic acid, or an ester thereof.

8. The method of claim 5 , the pharmaceutical composition comprising at least 75% of (S)-all-trans-13,14-dihydroretinol, (S)-all-trans-13,14-dihydroretinoic acid, or an ester thereof.

Assignments (1)
CONFIRMATORY LICENSE Recorded Feb 24, 2014
From: CASE WESTERN RESERVE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 032329/0839 →
Continuity (2)
Provisional Application 60851221 · Oct 12, 2006
Related Publication 20100135977A1 · Jun 3, 2010